AFP and hepatocellular carcinoma: In conclusion, chemotherapy using lenvatinib produced a high ORR in patients with BCLC stage B HCC or stage A HCC following prior TACE and/or TAI procedures, especially in those manifesting low serum AFP levels, and a favorable middle-term outcome was obtained in patients with mALBI grades 1 and 2a at baseline when they achieved a CR or PR according to mRECIST after between 4 and 8 weeks of therapy.